On June 13, 2026, at the Health and Wellbeing Sub-forum of the 18th Straits Forum, the group standard General Specification for Clinical Application of Hydrogen-Oxygen Mixed Gas Inhalation Therapy, jointly led and drafted by Asclepius Meditec together with the First Affiliated Hospital of Guangzhou Medical University (National Center for Respiratory Medicine) and Peking Union Medical College Hospital, was officially released. The standard fills a gap in hydrogen-oxygen industry regulation, marking that China's hydrogen-oxygen medicine has moved from empirical exploration into a new era of standardization and regularization.
Asclepius Meditec: the industry leader in hydrogen-oxygen medicine
As one of the joint lead organizations drafting the standard, Asclepius Meditec's contributions to hydrogen-oxygen medicine have earned high industry recognition; through years of in-depth research and technical innovation, the company has become an industry leader. It not only helped set this key industry standard, but its developed hydrogen-oxygen medical equipment has also been approved by the NMPA, providing reliable technical support for safe, standardized application of hydrogen-oxygen medicine.
Technical innovation: the safe choice that rejects traditional water electrolysis
Notably, Asclepius Meditec's hydrogen-oxygen machines explicitly do not adopt industrial hydrogen-production technology, avoiding the safety hazards of traditional alkaline water electrolysis (AEC) and proton exchange membrane electrolysis (PEM, also called SPE).
According to expert analysis, both mainstream water-electrolysis categories have clear flaws: the liquid-electrolyte process uses industrial strong alkali that can be inhaled into the airway with the gas and burn it, and devices overheat and cannot run continuously; the membrane used in the solid-conduction process (PFAS) is a hard-to-degrade forever chemical that causes long-term toxicity, raises cancer risk, and affects DNA and genetic inheritance; the EU has introduced PFAS restriction and prohibition regulations.
Asclepius Meditec's exclusively developed alkaline biocompatible conduction technology breaks through both AEC conductive-liquid electrolysis and PEM ion-membrane electrolysis barriers, delivering a medical-grade electrolysis solution that 'uses no membrane and adds no alkali,' and securing material safety at the source.
This provides a reliable technical path for the safe development of Chinese hydrogen-oxygen medicine. This choice fully reflects Asclepius Meditec's 'patient-safety-centered' product philosophy and sets a benchmark for device choice across the industry.
At the conference, Academician Zhong Nanshan emphasized that for long-term healthy development, hydrogen-oxygen medicine must 'hold to the core of evidence-based medicine' and 'pursue standardization first and standards-led guidance.' As an important participant in setting the industry standard, Asclepius Meditec will continue to lead the safe, beneficial application of this Chinese original technology and provide sustained support for the standardized, scientific, and regularized development of hydrogen-oxygen medicine.
